Resmed Shares Down 5.2% Premarket After U.S. FDA Approves Lilly's Weight-Loss Drug for Sleep Apnea
瑞思邁股票在盤前交易中下跌5.2%,因美國FDA批准利萊的減肥藥用於睡眠呼吸暫停症。
Resmed Shares Down 5.2% Premarket After U.S. FDA Approves Lilly's Weight-Loss Drug for Sleep Apnea
瑞思邁股票在盤前交易中下跌5.2%,因美國FDA批准利萊的減肥藥用於睡眠呼吸暫停症。
使用瀏覽器的分享功能,分享給你的好友吧